公共咨询

医疗器械登记 到 ANVISA

按号码、产品、持有公司或CNPJ搜索,数据是ANVISA在公开数据中发布的,每天都会到达这里。

记录的 ROCHE DIAGNÓSTICA BRASIL LTDA取消

310 记录

产品持有公司班级有效性
Elecsys BRAHMS PCT10287411521ROCHE DIAGNÓSTICA BRASIL LTDAIII23/03/2036
Elecsys CA 125 II10287411205ROCHE DIAGNÓSTICA BRASIL LTDAIII06/03/2037
Elecsys CA 15-3 II10287411291ROCHE DIAGNÓSTICA BRASIL LTDAIII06/11/2027
Elecsys CA 19-910287411218ROCHE DIAGNÓSTICA BRASIL LTDAIII24/04/2037
Elecsys CYFRA 21-110287411230ROCHE DIAGNÓSTICA BRASIL LTDAIII07/07/2035
Elecsys Calcitonin10287411576ROCHE DIAGNÓSTICA BRASIL LTDAIII06/10/2035
Elecsys Cyclosporine10287411036ROCHE DIAGNÓSTICA BRASIL LTDAIII10/02/2034
Elecsys Cyclosporine10287411217ROCHE DIAGNÓSTICA BRASIL LTDAIII24/04/2037
Elecsys Digitoxin10287411251ROCHE DIAGNÓSTICA BRASIL LTDAIII23/06/2035
Elecsys Digoxin10287411250ROCHE DIAGNÓSTICA BRASIL LTDAIII04/08/2035
Elecsys Digoxina10287411135ROCHE DIAGNÓSTICA BRASIL LTDAIII30/06/2035
Elecsys HCG+b10287411227ROCHE DIAGNÓSTICA BRASIL LTDAIII02/05/2037
Elecsys NSE10287411303ROCHE DIAGNÓSTICA BRASIL LTDAIII16/06/2035
Elecsys PAPP-A10287411304ROCHE DIAGNÓSTICA BRASIL LTDAIII19/02/2028
Elecsys PAPP-A 0886017319010287411621ROCHE DIAGNÓSTICA BRASIL LTDAIII05/09/2032
Elecsys PIVKA-II10287411626ROCHE DIAGNÓSTICA BRASIL LTDAIII19/09/2032
Elecsys Rubella IgM10287411314ROCHE DIAGNÓSTICA BRASIL LTDAIII26/02/2028
Elecsys S10010287411550ROCHE DIAGNÓSTICA BRASIL LTDAIII23/11/2030
Elecsys S100_0881732419010287411602ROCHE DIAGNÓSTICA BRASIL LTDAIII20/06/2032
Elecsys Tachrolimus10287411035ROCHE DIAGNÓSTICA BRASIL LTDAIII10/02/2034
Elecsys Tacrolimus10287411284ROCHE DIAGNÓSTICA BRASIL LTDAIII31/10/2027
Elecsys free ßhCG10287411533ROCHE DIAGNÓSTICA BRASIL LTDAIII21/09/2030
FAMÍLIA - AUTOTROL PLUS B10287410485ROCHE DIAGNÓSTICA BRASIL LTDAIII08/06/2036
FAMÍLIA D-DIMER10287411357ROCHE DIAGNÓSTICA BRASIL LTDAIII10/09/2028
FAMÍLIA ELECSYS MIOGLOBINA10287410324ROCHE DIAGNÓSTICA BRASIL LTDAIII07/07/2035

来源: ANVISA 开放数据,健康产品档案. 基础带来注册的有效性,而不是记录情况:注册可能在期限之前被取消,而不会在这里出现。 咨询门户 ANVISA.

接下来的步骤

您的产品需要在巴西注册

HSC在 ANVISA 中进行医疗器械登记,从风险类框架到过程跟踪。

联系专家